Product Description
OMS-405 is a small-molecule peroxisome proliferator-activated receptor gamma (PPARgamma ) agonist. (Sourced from: https://www.omeros.com/pipeline/#OMS405)
Mechanisms of Action: PPARg Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Omeros
Company Location: Western America
Company CEO: Gregory A. Demopulos
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Opioid-Related Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/27/2023 |
News Article |
Outlook on the Smoking Cessation and Nicotine Addiction Global Market to 2032 - Market Insight, Epidemiology And Market Forecast |
|
09/28/2021 |
News Article |
Cocaine Use Disorder Pipeline Evolves as Novel Therapeutic Assets Enter the Market |